Interim opioid agonist treatment for opioid addiction: a systematic review

Abstract Background Opioid use disorder is a public health problem and treatment variability, coverage and accessibility poses some challenges. The study’s objective is to review the impact of interim opioid agonist treatment (OAT), a short-term approach for patients awaiting standard OAT, in terms...

Full description

Bibliographic Details
Main Authors: Laura Samsó Jofra, Teresa Puig, Ivan Solà, Joan Trujols
Format: Article
Language:English
Published: BMC 2022-01-01
Series:Harm Reduction Journal
Subjects:
Online Access:https://doi.org/10.1186/s12954-022-00592-x
_version_ 1828867066542686208
author Laura Samsó Jofra
Teresa Puig
Ivan Solà
Joan Trujols
author_facet Laura Samsó Jofra
Teresa Puig
Ivan Solà
Joan Trujols
author_sort Laura Samsó Jofra
collection DOAJ
description Abstract Background Opioid use disorder is a public health problem and treatment variability, coverage and accessibility poses some challenges. The study’s objective is to review the impact of interim opioid agonist treatment (OAT), a short-term approach for patients awaiting standard OAT, in terms of treatment retention, access to standard OAT, quality of life and satisfaction with treatment. Method We conducted a systematic review searching MEDLINE, EMBASE, PsycINFO, and CENTRAL up to May 2020. Due to variability between studies and outcome measurements, we did not pool effect estimates and reported a narrative synthesis of findings rating their certainty according to GRADE. Results We identified 266 unique records and included five randomized trials with some limitations in risk of bias and one observational study limited by selection bias. The studies assessed similar approaches to interim OAT but were compared to three different control conditions. Four studies reported on treatment retention at 4 months or less with no significant differences between interim OAT and waiting list or standard OAT. Two studies reported treatment retention at 12 months with no differences between interim OAT and standard OAT. Two trials assessed access to standard OAT and showed significant differences between interim OAT and waiting list for standard OAT. We rated the quality of evidence for these outcomes as moderate due to the impact of risk of bias. Data on quality of life or satisfaction with treatment was suboptimal. Conclusions Interim OAT is likely more effective than a waiting list for standard OAT in access to treatment, and it is probably as effective as standard OAT regarding treatment retention. PROSPERO registration CRD42018116269.
first_indexed 2024-12-13T05:03:50Z
format Article
id doaj.art-8a8989cf3d3745f39973570a61c9be5a
institution Directory Open Access Journal
issn 1477-7517
language English
last_indexed 2024-12-13T05:03:50Z
publishDate 2022-01-01
publisher BMC
record_format Article
series Harm Reduction Journal
spelling doaj.art-8a8989cf3d3745f39973570a61c9be5a2022-12-21T23:58:43ZengBMCHarm Reduction Journal1477-75172022-01-0119111810.1186/s12954-022-00592-xInterim opioid agonist treatment for opioid addiction: a systematic reviewLaura Samsó Jofra0Teresa Puig1Ivan Solà2Joan Trujols3Department of Epidemiology and Public Health, Hospital de la Santa Creu i Sant PauDepartment of Epidemiology and Public Health, Hospital de la Santa Creu i Sant PauDepartment of Epidemiology and Public Health, Hospital de la Santa Creu i Sant PauBiomedical Research Institute Sant Pau (IIB Sant Pau)Abstract Background Opioid use disorder is a public health problem and treatment variability, coverage and accessibility poses some challenges. The study’s objective is to review the impact of interim opioid agonist treatment (OAT), a short-term approach for patients awaiting standard OAT, in terms of treatment retention, access to standard OAT, quality of life and satisfaction with treatment. Method We conducted a systematic review searching MEDLINE, EMBASE, PsycINFO, and CENTRAL up to May 2020. Due to variability between studies and outcome measurements, we did not pool effect estimates and reported a narrative synthesis of findings rating their certainty according to GRADE. Results We identified 266 unique records and included five randomized trials with some limitations in risk of bias and one observational study limited by selection bias. The studies assessed similar approaches to interim OAT but were compared to three different control conditions. Four studies reported on treatment retention at 4 months or less with no significant differences between interim OAT and waiting list or standard OAT. Two studies reported treatment retention at 12 months with no differences between interim OAT and standard OAT. Two trials assessed access to standard OAT and showed significant differences between interim OAT and waiting list for standard OAT. We rated the quality of evidence for these outcomes as moderate due to the impact of risk of bias. Data on quality of life or satisfaction with treatment was suboptimal. Conclusions Interim OAT is likely more effective than a waiting list for standard OAT in access to treatment, and it is probably as effective as standard OAT regarding treatment retention. PROSPERO registration CRD42018116269.https://doi.org/10.1186/s12954-022-00592-xOpioid use disorderOpioid agonist treatmentInterim treatmentMethadoneBuprenorphineSystematic review
spellingShingle Laura Samsó Jofra
Teresa Puig
Ivan Solà
Joan Trujols
Interim opioid agonist treatment for opioid addiction: a systematic review
Harm Reduction Journal
Opioid use disorder
Opioid agonist treatment
Interim treatment
Methadone
Buprenorphine
Systematic review
title Interim opioid agonist treatment for opioid addiction: a systematic review
title_full Interim opioid agonist treatment for opioid addiction: a systematic review
title_fullStr Interim opioid agonist treatment for opioid addiction: a systematic review
title_full_unstemmed Interim opioid agonist treatment for opioid addiction: a systematic review
title_short Interim opioid agonist treatment for opioid addiction: a systematic review
title_sort interim opioid agonist treatment for opioid addiction a systematic review
topic Opioid use disorder
Opioid agonist treatment
Interim treatment
Methadone
Buprenorphine
Systematic review
url https://doi.org/10.1186/s12954-022-00592-x
work_keys_str_mv AT laurasamsojofra interimopioidagonisttreatmentforopioidaddictionasystematicreview
AT teresapuig interimopioidagonisttreatmentforopioidaddictionasystematicreview
AT ivansola interimopioidagonisttreatmentforopioidaddictionasystematicreview
AT joantrujols interimopioidagonisttreatmentforopioidaddictionasystematicreview